您好，欢迎光临上海雅吉生物商城！
工作时间：9:00-18:00
全国服务热线：021-34661276
请登录免费注册 我的订单我要询价

所有产品分类

当前位置：首页 > 抗体蛋白 > 抗体> PE anti-mouse IFN-γ Antibody

PE anti-mouse IFN-γ Antibody

订购数量：
加入购物车
加入收藏夹
规格
价格库存
订购热线：021-34661276
收藏此商品
我要询价
  • 商品详情
  • 售后服务
  • 相关文献

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The IFN-γ antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard.
ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-? (Cat. No. 575309) as the standard. The LEAF? purified antibody is suggested for ELISPOT capture (Cat. No. 505812).
Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-?-producing cells within mixed cell populations.
Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-?. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of mouse IFN-? bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).
Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry.
Note: For testing mouse IFN-? in serum, plasma or supernatant, BioLegend's ELISA Max? Sets (Cat. No. 430801 to 430806) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut)
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut)
  3. Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut)
  4. Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA)
  5. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT)
  6. Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC)
  7. Ferrick D, et al. 1995. Nature 373:255. (FC)
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  9. Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut)
  10. DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut)
  11. Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA)
  12. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  13. Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed
  14. Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed
  15. Montfort M, et al.2004. J. Immunol. 173:4084. PubMed
  16. Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed
  17. Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed
  18. Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed
  19. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  20. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed
  21. Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed
  22. Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC)
  23. Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations
  1. Wang H, et al. 2013. J Immunol. 191:6010. PubMed
  2. Kim K, et al. 2016. PLoS One. 11: 0148576. PubMed
  3. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  4. Chen Y, et al. 2020. Virol Sin. . PubMed
  5. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  6. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  7. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  8. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  9. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  10. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  11. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  12. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  13. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  14. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  15. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  16. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  17. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  18. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  19. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  20. Xia S, et al. 2014. J Leukoc Biol. 95:733. PubMed
  21. Su N, Xiong Y 2016. Sci Rep. 6:22658. PubMed
  22. Dong L, et al. 2021. Cancer Cell. . PubMed
  23. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  24. Wang X, et al. 2018. Int Immunopharmacol. 56:249. PubMed
  25. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  26. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  27. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  28. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  29. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  30. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  31. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  32. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  33. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  34. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  35. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  36. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  37. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  38. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  39. Herman JD, et al. 2021. Nat Commun. 12:6853. PubMed
  40. Galeano Ni?o JL, et al. 2020. J Cell Sci. . PubMed
  41. Saito S, et al. 2020. Nutrients. 12:. PubMed
  42. Koenecke C, et al. 2012. J Immunol. 189:2890. PubMed
  43. Michel M, et al. 2012. Proc Natl Acad Sci U S A. 109:17459. PubMed
  44. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  45. Chen D, et al. 2018. Nat Commun. 9:873. PubMed
  46. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  47. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  48. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  49. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  50. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  51. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  52. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  53. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  54. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  55. Kuttke M, et al. 2022. Front Immunol. 13:695576. PubMed
  56. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  57. Subbiah J, et al. 2022. NPJ Vaccines. 7:68. PubMed
  58. Wang C, et al. 2021. Cell Rep. 37:110021. PubMed
  59. Wan Y, et al. 2014. Vaccine. 41:241. PubMed
  60. Sandrock I, et al. 2015. PLoS One. 10: 0145010. PubMed
  61. Koren N, et al. 2021. Cell Host Microbe. 29(2):197-209.e5. PubMed
  62. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  63. Probst P, et al. 2017. Cancer Res. 77:3644. PubMed
  64. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  65. An J, et al. 2022. iScience. 25:103570. PubMed
  66. Han JP, et al. 2022. Sci Adv. 8:eabj6901. PubMed
  67. Shami A, et al. 2015. Sci Rep. 5: 13904. PubMed
  68. Gungor B, et al. 2014. Sci Transl Med. 6:235. PubMed
  69. Hegde S, et al. 2020. Cancer Cell. 37(3):289-307. PubMed
  70. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  71. Chen D, et al. 2022. J Neuroinflammation. 19:112. PubMed
  72. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  73. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  74. Cho K, Hill A 2008. J Immunol Methods. 330:137. PubMed
  75. Condotta S, et al. 2015. J Immunol. 195: 116 - 125. PubMed
  76. Satoh M, et al. 2016. Sci Rep. 6:28473. PubMed
  77. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  78. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  79. Hundt M, et al. 2009. J Immunol. 183:1685. PubMed
  80. Duan RN, et al. 2021. J Neuroinflammation. 18:145. PubMed
  81. Hanasoge Somasundara AV, et al. 2021. Cell Rep. 37:110099. PubMed
  82. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  83. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  84. Sartorius R, et al. 2015. EMBO Mol Med. 7: 973 - 988. PubMed
  85. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  86. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  87. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  88. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  89. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  90. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  91. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  92. Ma Y, et al. 2013. J Immunol. 190:5588. PubMed
  93. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  94. QT N, et al. 2015. Antimicrob Agents Chemother. 59: 6308-6316. PubMed
  95. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  96. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  97. Galeano Ni?o JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  98. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  99. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  100. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  101. Tian X, et al. 2022. J Cell Mol Med. 26:693. PubMed
  102. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  103. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  104. Ren Y, et al. 2015. Sci Rep. 5: 18099. PubMed
  105. Kraus Z, et al. 2008. J Immunol. 181:7800. PubMed
  106. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  107. Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
  108. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  109. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  110. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  111. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  112. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  113. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  114. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  115. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  116. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  117. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  118. Montfort M, et al. 2004. J Immunol. 173:4084. PubMed
  119. Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
  120. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  121. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  122. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  123. Castiglioni P, et al. 2017. PLoS Negl Trop Dis. 10.1371/journal.pntd.0005240. PubMed
  124. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  125. Roy S, et al. 2019. Front Immunol. 2.404166667. PubMed
  126. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  127. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  128. Zhang J, et al. 2018. Nature. 553:91. PubMed
  129. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  130. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  131. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  132. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  133. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  134. Miao W, et al. 2020. J Immunol. 1486:204. PubMed
  135. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  136. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  137. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  138. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  139. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  140. Mah-Som AY, et al. 2021. Cell Reports. 35(9):109209. PubMed
  141. Lee J, et al. 2007. Nat Immunol. 8:181. PubMed
  142. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  143. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  144. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  145. Johnson RM, et al. 2021. Front Immunol. 11:614697. PubMed
  146. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  147. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  148. Tomaru U et al. 2019. Cell reports. 26(3):639-651 . PubMed
  149. Molgora M, et al. 2020. Cell. 182:886. PubMed
  150. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  151. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  152. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  153. Wang Y, et al. 2021. Front Immunol. 11:601601. PubMed
  154. Prakash MD, et al. 2021. PLoS One. 16:e0247492. PubMed
  155. Zhang X, et al. 2020. J Cancer. 11:648. PubMed
  156. Zhao K, et al. 2021. Biomed Res Int. 7619849:2020. PubMed
  157. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  158. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  159. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  160. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  161. Li H, et al. 2022. iScience. 25:104481. PubMed
  162. Zhang X, et al. 2021. Front Pharmacol. 12:706748. PubMed
  163. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  164. Gaylo A, et al. 2013. Transpl Immunol. 20:163. PubMed
  165. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  166. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  167. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  168. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  169. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  170. Zheng Y, et al. 2022. Transl Res. :. PubMed
  171. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  172. Chow AK, et al. 2021. Cellular and Molecular Gastroenterology and Hepatology. :. PubMed
  173. Tripathi D, et al. 2016. Nat Commun. 7:13896. PubMed
  174. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  175. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  176. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  177. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  178. Chen PM, et al. 2022. Sci Adv. 8:eabo4271. PubMed
  179. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  180. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  181. Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID
AB_315401 (BioLegend Cat. No. 505807) AB_315402 (BioLegend Cat. No. 505808)

Antigen Details

Structure
Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID
15978 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org
我要询价
*联系方式：
(可以是QQ、MSN、电子邮箱、电话等，您的联系方式不会被公开)
*内容：

  • 扫码咨询微信客服

  • 扫码咨询微信客服

首页 产品专区 品牌专区 技术资讯 关于我们 付款方式 联系我们

©Copyright 上海雅吉生物科技有限公司 All Rights Reserved. ICP备案号：沪ICP备18032507号-1 技术支持：阿仪网


微信客服
扫一扫立即咨询


微信客服
扫一扫立即咨询

销售电话：

021-34661275

021-34661276

15301693058